IDENTIFICATION AND SCREENING OF BACE1 INHIBITORS AGAINST TYPE 2 DIABETES USING DRUG REPURPOSING A DISSERTATION

Abstract

Type 2 diabetes (T2D) is a complicated disease that is caused by a complicated combination of hereditary, environmental, and epigenetic factors. Chronic diabetes-related hyperglycemia is linked with dysfunction, long-lasting damage, and failure of several organs, including the blood vessels, heart, eyes, kidneys, and nerves. An interaction involving genes as well as the environment has been linked to diabetes, which is presently the pandemic with the fastest rate of growth. Research on BACE1 has earlier concentrated on its functions as the 13-secretase that regulates the synthesis of 13-amyloid beta, which is seen in Alzheimer's disease. BACE1 expression that is pathologically high in cells that have been linked to the emergence of metabolic diseases like type 2 diabetes, heart diseases, and obesity. Multiple drugs are present in the market to treat the disease, but more drugs are required to be easily accessible to the public. This could be possible when a drug that is normally used for less harmful diseases like fever, nausea, and many more are repurposed to treat chronic diseases like type 2 diabetes (T2D). In this research, anti-viral drugs and anti-hypertension drugs have been repurposed using the in-silico approach of molecular docking which inhibits the BACE1 protein. When this protein is inhibited, it stops the chances of occurrence of type 2 diabetes. Telmisartan, an anti-hypertensive drug, is the best drug to limit the action of BACE1 protein to stop the progression of the disease.